» Articles » PMID: 20191374

Clinical Features of Pediatric Graves' Orbitopathy

Overview
Journal Int Ophthalmol
Specialty Ophthalmology
Date 2010 Mar 2
PMID 20191374
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Pediatric Graves' orbitopathy is rare, thus its clinical picture is less well defined in comparison with the adult population. Therefore it is our aim to describe the clinical spectrum at our tertiary referral center. We identified 11 patients under the age of 18 years (3♂, 8♀; range 3-16 years, mean age 14.5 years) with Graves' disease and signs of orbitopathy. Seven of them where reevaluated (mean follow-up 25 months, range 3-66 months). Eyelid retraction and proptosis were the predominant signs in 10/11 of our patients. In six patients, Hertel readings ranged from 22 mm or above. Mild ocular motility impairment was seen in four children. Active orbitopathy or severe impairment of visual acuity/ocular motility, corneal or optic nerve involvement was not observed in our study. Our series confirms that pediatric Graves' orbitopathy lacks significant inflammatory features; however, proptosis is common and may be marked. All seven patients who were reevaluated did not show any clinically significant change of ocular signs during the observation period. In particular, there was no improvement of proptosis despite restoration of euthyroidism.

Citing Articles

Efficacy of Tocilizumab in Refractory Graves Orbitopathy From Real-World Clinical Practice: An Observational Study.

Wang M, Qin B, Liu C, Liu H, Li D J Endocr Soc. 2024; 8(12):bvae193.

PMID: 39564579 PMC: 11574614. DOI: 10.1210/jendso/bvae193.


Graves' Orbitopathy: Report of 82 cases.

Mbarek S, Abid F, Ammari W, Alaya W, Mahmoud A, Messaoud R Tunis Med. 2021; 99(2):243-251.

PMID: 33899194 PMC: 8724701.


[Role and effectiveness of radioactive-iodine therapy for the treatment of Grave's disease].

Sellem A, Elajmi W, Mhamed R, Oueslati N, Ouertani H, Hammami H Pan Afr Med J. 2020; 36:341.

PMID: 33193994 PMC: 7603816. DOI: 10.11604/pamj.2020.36.341.21623.


Incidence and clinical characteristics of pediatric eyelid retraction.

Olayanju J, Griepentrog G, Mohney B J AAPOS. 2019; 23(4):213.e1-213.e4.

PMID: 31229605 PMC: 7006648. DOI: 10.1016/j.jaapos.2019.03.004.


Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease.

Jarusaitiene D, Verkauskiene R, Jasinskas V, Jankauskiene J Int J Endocrinol. 2016; 2016:8129497.

PMID: 27413373 PMC: 4928005. DOI: 10.1155/2016/8129497.


References
1.
Acuna O, Athannassaki I, Paysse E . Association between thyroid-stimulating immunoglobulin levels and ocular findings in pediatric patients with Graves disease. Trans Am Ophthalmol Soc. 2008; 105:146-50. PMC: 2258108. View

2.
Rivkees S, Sklar C, Freemark M . Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab. 1998; 83(11):3767-76. DOI: 10.1210/jcem.83.11.5239. View

3.
Wong G, Cheng P . Increasing incidence of childhood Graves' disease in Hong Kong: a follow-up study. Clin Endocrinol (Oxf). 2001; 54(4):547-50. DOI: 10.1046/j.1365-2265.2001.01252.x. View

4.
Prummel M, Bakker A, Wiersinga W, Baldeschi L, Mourits M, Kendall-Taylor P . Multi-center study on the characteristics and treatment strategies of patients with Graves' orbitopathy: the first European Group on Graves' Orbitopathy experience. Eur J Endocrinol. 2003; 148(5):491-5. DOI: 10.1530/eje.0.1480491. View

5.
Bartley G, Fatourechi V, Kadrmas E, Jacobsen S, Ilstrup D, Garrity J . Clinical features of Graves' ophthalmopathy in an incidence cohort. Am J Ophthalmol. 1996; 121(3):284-90. DOI: 10.1016/s0002-9394(14)70276-4. View